Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026
BOULDER, Colo., May 04, 2026 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the first quarter ended March 31, 2026.
BOULDER, Colo., May 04, 2026 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the first quarter ended March 31, 2026.
CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Chapel Hill, N.C., May 4, 2026 - James River Group Holdings, Inc. ("James River" or the "Company") (NASDAQ: JRVR) today reported the following results for the first quarter of 2026 as compared to the same period in 2025:
CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Chapel Hill, N.C., May 4, 2026 - James River Group Holdings, Inc. ("James River" or the "Company") (NASDAQ: JRVR) today reported the following results for the first quarter of 2026 as compared to the same period in 2025:
OAKLAND, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, announced today its financial results for the first quarter ended March 31, 2026 and updated full year 2026 financial outlook.
OAKLAND, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, announced today its financial results for the first quarter ended March 31, 2026 and updated full year 2026 financial outlook.
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- EverQuote, Inc. (Nasdaq: EVER), a leading provider of growth solutions for property and casualty, or P&C, insurance providers, today announced financial results for the first quarter ended March 31, 2026.
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- EverQuote, Inc. (Nasdaq: EVER), a leading provider of growth solutions for property and casualty, or P&C, insurance providers, today announced financial results for the first quarter ended March 31, 2026.
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2026.
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2026.
Signed new license agreements with AMD and MicrosoftGenerated $58 million in cash from operations and achieved 60% adjusted EBITDA marginPaid down debt by $28 million bringing our outstanding balance to less than $400 million SAN JOSE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”) today announced financial results for the first quarter ended March 31...
Signed new license agreements with AMD and MicrosoftGenerated $58 million in cash from operations and achieved 60% adjusted EBITDA marginPaid down debt by $28 million bringing our outstanding balance to less than $400 million SAN JOSE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”) today announced financial results for the first quarter ended March 31, 2026. “We had a strong start to 2026, delivering first quarter revenue of $105 million, generating
Palantir Reports Q1 2026 U.S. Revenue Growth of 104% Y/Y and Revenue Growth of 85% Y/Y; Raises FY 2026 Revenue Guidance to 71% Y/Y Growth and U.S. Comm Revenue Guidance to 120% Y/Y, Crushing Consensus Expectations Yahoo Finance Here's How Much Traders Expect Palantir Stock to Move After Earnings Investopedia Palantir Technologies perks up as Q1 results, guidance top Wall Street's forecast (PLTR:NA...
Palantir Reports Q1 2026 U.S. Revenue Growth of 104% Y/Y and Revenue Growth of 85% Y/Y; Raises FY 2026 Revenue Guidance to 71% Y/Y Growth and U.S. Comm Revenue Guidance to 120% Y/Y, Crushing Consensus Expectations Yahoo Finance Here's How Much Traders Expect Palantir Stock to Move After Earnings Investopedia Palantir Technologies perks up as Q1 results, guidance top Wall Street's forecast (PLTR:NASDAQ) Seeking Alpha
Inspire Medical Systems press release ( INSP ): Q1 Non-GAAP EPS of $0.10 beats by $0.36 . Revenue of $204.58M (+1.6% Y/Y) beats by $4.55M . Full Year 2026 Guidance The Company is revising its previously announced revenue outlook to be in the range of $825 million to $875 million, which represents a decline of 4% to 10% compared to 2025. Additionally, the Company now expects annual adjusted operati...
Inspire Medical Systems press release ( INSP ): Q1 Non-GAAP EPS of $0.10 beats by $0.36 . Revenue of $204.58M (+1.6% Y/Y) beats by $4.55M . Full Year 2026 Guidance The Company is revising its previously announced revenue outlook to be in the range of $825 million to $875 million, which represents a decline of 4% to 10% compared to 2025. Additionally, the Company now expects annual adjusted operating margin in the range of 2% to 4%, diluted EPS in the range of $0.07 to $0.62 and adjusted diluted EPS in the range of $0.75 to $1.25. More on Inspire Medical Systems Inspire Medical Systems, Inc. (INSP) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript Inspire Medical: Sleeping Giant Awakens The OSA Implant Market, Initiating With A Buy Inspire Medical: Still A Long Way From A Good Night's Sleep Inspire Medical Systems Q1 2026 Earnings Preview Inspire Medical surges after KeyBanc sees CMS adding codes for Inspire V implant
July ICE NY cocoa (CCN26 ) on Monday closed up +287 (+7.98%), and July ICE London cocoa #7 (CAN26 ) did not trade with markets in the UK closed for the May Day holiday. Cocoa prices rallied sharply on Monday, as NY cocoa posted a 2.75-month high. The prolonged closure...
July ICE NY cocoa (CCN26 ) on Monday closed up +287 (+7.98%), and July ICE London cocoa #7 (CAN26 ) did not trade with markets in the UK closed for the May Day holiday. Cocoa prices rallied sharply on Monday, as NY cocoa posted a 2.75-month high. The prolonged closure...
July NY world sugar #11 (SBN26 ) on Monday closed up +0.34 (+2.27%), and Aug London ICE white sugar #5 (SWQ26 ) did not trade as markets in the UK were closed for the May Day holiday. Sugar prices settled sharply higher on Monday for a second day, with NY...
July NY world sugar #11 (SBN26 ) on Monday closed up +0.34 (+2.27%), and Aug London ICE white sugar #5 (SWQ26 ) did not trade as markets in the UK were closed for the May Day holiday. Sugar prices settled sharply higher on Monday for a second day, with NY...
July arabica coffee (KCN26 ) on Monday closed down -0.90 (-0.31%), and July ICE robusta coffee (RMN26 ) did not trade as UK markets were closed for the May Day holiday. Arabica coffee gave up an early advance on Monday and settled lower, weighed down by a stronger dollar. Prices...
July arabica coffee (KCN26 ) on Monday closed down -0.90 (-0.31%), and July ICE robusta coffee (RMN26 ) did not trade as UK markets were closed for the May Day holiday. Arabica coffee gave up an early advance on Monday and settled lower, weighed down by a stronger dollar. Prices...
Viper Energy press release ( VNOM ): Q1 Non-GAAP EPS of $1.22 beats by $0.69 . Q1 2026 average production of 65,000 bo/d (130,711 boe/d) Q1 2026 lease bonus income of $15 million During Q1 2026, repurchased 2.2 million shares of the Company’s common stock (including both Class A shares and Class B shares paired with OpCo units) for an aggregate purchase price of approximately $96 million, excludin...
Viper Energy press release ( VNOM ): Q1 Non-GAAP EPS of $1.22 beats by $0.69 . Q1 2026 average production of 65,000 bo/d (130,711 boe/d) Q1 2026 lease bonus income of $15 million During Q1 2026, repurchased 2.2 million shares of the Company’s common stock (including both Class A shares and Class B shares paired with OpCo units) for an aggregate purchase price of approximately $96 million, excluding excise tax (average price of $43.59 per share) Total Q1 2026 return of capital to Class A stockholders of $183 million, or $0.94 per Class A common share, represents 90% of cash available for distribution As of March 31, 2026, the Company had $28 million in cash and total debt outstanding (excluding debt issuance costs, discounts and premiums) of $1.62 billion, resulting in net debt (as defined and reconciled below) of $1.59 billion, or a decrease of $600 million in net debt from December 31, 2025 GUIDANCE UPDATE Below is Viper’s guidance for the full year 2026, as well as average production guidance for Q2 2026. This guidance does not give effect to the pending Riverbend Acquisition announced today. Viper Energy, Inc. Q2 2026 Net Production - Mbo/d 64.0 - 65.0 Q2 2026 Net Production - Mboe/d 124.0 - 126.0 Full Year 2026 Net Production - Mbo/d 64.5 - 66.5 Full Year 2026 Net Production - Mboe/d 126.0 - 130.0 Unit costs ($/boe) Depletion $16.25 - $18.25 Cash G&A $0.70 - $0.90 Non-Cash Share-Based Compensation $0.10 - $0.20 Net Interest Expense $1.90 - $2.40 Production and Ad Valorem Taxes (% of Revenue) ~7% Cash Tax Rate (% of Pre-Tax Income Attributable to the Company) (1) 27% - 30% Q2 2026 Cash Taxes ($ - million) (2) $40 - $48 Click to enlarge More on Viper Energy Viper Energy: A High-Margin Royalty Machine With 10% Yield Potential Viper Energy: Oil Spike Reinforces The Case For This High-Yield Permian Royalty Play Viper Energy: A Lot Of Catching Up Needed Viper Energy hiked to Buy at Jefferies as valuation primed for upside Viper Energy announces pricing of secondary of...
German defense contractor Rheinmetall ( RNMBF ) ( RNMBY ) reported stronger first-quarter results, with revenue rising 7.7% year over year to €1.94 billion ($2.27 billion), the company said Monday. Operating profit increased to €224 million from €191 million a year earlier, lifting the margin to 11.6% from 10.5%, according to preliminary figures. The company expects momentum to pick up in the seco...
German defense contractor Rheinmetall ( RNMBF ) ( RNMBY ) reported stronger first-quarter results, with revenue rising 7.7% year over year to €1.94 billion ($2.27 billion), the company said Monday. Operating profit increased to €224 million from €191 million a year earlier, lifting the margin to 11.6% from 10.5%, according to preliminary figures. The company expects momentum to pick up in the second quarter, supported by increased deliveries of weapons and ammunition as production ramps up at its Murcia facility in Spain, along with vehicle shipments to a German customer. Rheinmetall reaffirmed its outlook for 2026, projecting revenue growth of 40% to 45% and an operating margin of about 19%, signaling confidence that defense demand will remain strong. More on Rheinmetall AG Rheinmetall: A Multi-Combat System Provider At The Start Of A NATO Spending Super Cycle Rheinmetall: The Defense Supercycle Is Far Bigger Than Investors Think Rheinmetall AG (RHM:CA) Q4 2025 Earnings Call Transcript Citi upgrades European defense names, sees limited upside for Rheinmetall Rheinmetall says Iveco military trucks deal pushed back as Leonardo transaction takes longer
Vertex Pharmaceuticals press release ( VRTX ): Q1 Non-GAAP EPS of $4.47 beats by $0.16 . Revenue of $2.99B (+7.9% Y/Y) misses by $10M . Total revenue increased 8% to $2.99 billion compared to the first quarter of 2025, primarily driven by the continued performance of cystic fibrosis ( CF ) therapies and growth from diversification into additional disease areas. In the U.S. , total revenue increase...
Vertex Pharmaceuticals press release ( VRTX ): Q1 Non-GAAP EPS of $4.47 beats by $0.16 . Revenue of $2.99B (+7.9% Y/Y) misses by $10M . Total revenue increased 8% to $2.99 billion compared to the first quarter of 2025, primarily driven by the continued performance of cystic fibrosis ( CF ) therapies and growth from diversification into additional disease areas. In the U.S. , total revenue increased 7% to $1.78 billion due to continued strong CF patient demand, including from new initiations of ALYFTREK; higher realized net prices in CF versus the prior year; and contributions from CASGEVY and JOURNAVX. Outside the U.S. , total revenue increased 9% to $1.21 billion due to strong CF performance across multiple geographies, including ALYFTREK uptake, increased CASGEVY revenue, and a favorable impact from foreign exchange. FY revenue consensus $13.05B Vertex’s financial guidance is summarized below: Current FY 2026 Previous FY 2026 Total revenue Unchanged $12.95 to $13.1 billion Non-CF product revenue Unchanged $0.5 billion or greater Combined GAAP R&D, AIPR&D and SG&A expenses * Unchanged $6.3 to $6.45 billion Combined non-GAAP R&D, AIPR&D and SG&A expenses* Unchanged $5.65 to $5.75 billion Non-GAAP effective tax rate Unchanged 19.5% to 20.5% Click to enlarge More on Vertex Pharmaceuticals Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech Vertex Pharma wins FDA label expansion for cystic fibrosis therapies
Image source: The Motley Fool. Wednesday, February 25, 2026 at 11:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
Image source: The Motley Fool. Wednesday, February 25, 2026 at 11:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading